60 A recent systematic review found that there is little evidence for a physiologically relevant cephalic phase insulin response, although more than half of the studies examined documented its presence
However, treatment with equimolar doses of GLP1/E markedly improved body weight, food intake, fat mass, leptin levels, glucose metabolism, insulin sensitivity, and circulating insulin levels with far superior efficacy as compared with GLP1 and E monotherapies (Fig
To qualify for the Medicare GLP-1 Bridge program, patients must be classified as obese, meaning they have a body mass index (BMI) of 30 or greater
Slow dose escalation mitigates these effects substantially, and discontinuation due to gastrointestinal intolerance ranges from 3% to 16% across agents, being highest for GLP-1/glucagon dual agonists (e.g., survodutide)
Use bacteriostatic water for reconstitution if you plan to use the solution over multiple days
The slowed gastric emptying means large meals sit uncomfortably